CareDx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CareDx and other ETFs, options, and stocks.

About CDNA

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. 

CEO
John W. Hanna
CEOJohn W. Hanna
Employees
765
Employees765
Headquarters
Brisbane, California
HeadquartersBrisbane, California
Founded
1998
Founded1998
Employees
765
Employees765

CDNA Key Statistics

Market cap
1.24B
Market cap1.24B
Price-Earnings ratio
-149.06
Price-Earnings ratio-149.06
Dividend yield
Dividend yield
Average volume
784.29K
Average volume784.29K
High today
$24.13
High today$24.13
Low today
$22.73
Low today$22.73
Open price
$23.02
Open price$23.02
Volume
903.92K
Volume903.92K
52 Week high
$24.13
52 Week high$24.13
52 Week low
$10.96
52 Week low$10.96

Stock Snapshot

CareDx(CDNA) stock is priced at $24.06, giving the company a market capitalization of 1.24B. It carries a P/E multiple of -149.06.

During the trading session on 2026-06-15, CareDx(CDNA) shares reached a daily high of $24.13 and a low of $22.73. At a current price of $24.06, the stock is +5.9% higher than the low and still -0.3% under the high.

Trading volume for CareDx(CDNA) stock has reached 903.92K, versus its average volume of 784.29K.

Over the past 52 weeks, CareDx(CDNA) stock has traded between a high of $24.13 and a low of $10.96.

Over the past 52 weeks, CareDx(CDNA) stock has traded between a high of $24.13 and a low of $10.96.

CDNA News

TipRanks 2h
CareDx Shareholders Back Directors, Auditor and Equity Plan

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Investing.com 4d
Caredx Inc stock hits 52-week high at $24.04 - Investing.com

...

Caredx Inc stock hits 52-week high at $24.04 - Investing.com
Simply Wall St 5d
Did CareDx’s Naveris Deal and Oncology Pivot Just Redefine CDNA’s Investment Narrative?

In early June 2026, CareDx reported Q1 revenue growth of 39% year over year, raised full-year guidance to US$447–US$465 million with adjusted EBITDA of US$43–US...

Did CareDx’s Naveris Deal and Oncology Pivot Just Redefine CDNA’s Investment Narrative?

Analyst ratings

57%

of 7 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

People also own

Based on the portfolios of people who own CDNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.